Pancreatic ductal adenocarcinoma (PDAC) is the most common form of pancreatic cancer and lacks effective therapies, driving dismal survival. Because most patients present with metastatic disease, when curative intervention is no longer possible, there is an urgent unmet need for biomarker panels that enable early det...
Ariana Musa de Aquino, Guillaume Cognet, Alexa Lupi et al.· Cancer Research· 0 citations
Pancreatic ductal adenocarcinoma (PDAC) is among the deadliest cancer types in the United States, with over 90% of tumors driven by oncogenic KRAS. Several KRAS inhibitors have demonstrated promising preclinical or early clinical efficacy; however, their therapeutic benefit is limited by the emergence of acquired...
Saurabh Mandal, M. Bharmal, Swathi Sridhar et al.· Cancer Research· 0 citations
The findings reveal distinct metastatic microenvironments in liver and lung characterized by coordinated differences in tumor subtype composition and myeloid phenotype, highlighting the importance of local immune landscapes in shaping metastatic disease biology.
E. Lasse-Opsahl, Daksh Thakkar, Julie M. Clark et al.· Cancer Research· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.